

1 **Implementation strategies to increase human papillomavirus vaccination** 2 **uptake for adolescent girls in sub-Saharan Africa: A scoping review protocol**

3 Mwansa Ketty Lubeya^{1,2,3}, Mulindi Mwanahamuntu^{1,2}, Carla Chibwasha⁴, Moses Mukosha⁵,
4 Mercy Monde Wamunyima⁶, Mary Kawonga³

5 **Affiliations**

6 ¹Department of Obstetrics and Gynaecology, School of Medicine, The University of Zambia,
7 Lusaka, Zambia

8 ²Women and Newborn Hospital, University Teaching Hospitals, Lusaka, Zambia

9 ³School of public health, Faculty of Health Sciences, University of the Witwatersrand,
10 Johannesburg, South Africa

11 ⁴Clinical HIV Research Unit, Helen Joseph Hospital, Johannesburg, South Africa

12 ⁵Department of Pharmacy, School of Health Sciences, University of Zambia, Lusaka, Zambia

13 ⁶School of Medicine Library, The University of Zambia, Lusaka, Zambia

14 **Corresponding author:** Mwansa Ketty Lubeya ketty.lubeya@unza.zm

15 **Abstract**

16 **Introduction:** The human papillomavirus (HPV) is sexually transmitted and infects
17 approximately 75% of sexually active people early in their sexual life. Persistent infection with
18 oncogenic HPVtypes can lead to malignant conditions such as cervical cancer. In 2006, the
19 World Health Organisation approved the use of efficacious HPV vaccine for girls aged 9 to 14
20 years to prevent HPV related conditions. Despite the HPV vaccine having been available for
21 about 15 years, dose completion remains at 53% in sub-Saharan Africa for countries
22 implementing the vaccination program. A fraught of barriers to implementation exist which
23 prevent adequate coverage. Achieving success for HPV vaccination in real-world settings
24 requires enacted implementation strategies to overcome implementation bottlenecks. Therefore,
25 a better understanding and mapping of the implementation strategies used in sub-Saharan Africa
26 to increase HPV vaccination uptake is critical. This review aims to identify implementation

27 strategies to increase HPV vaccination uptake for adolescent girls in sub-Saharan Africa and
28 provide a basis for policy and future research including systematic reviews to evaluate effective
29 strategies as we accelerate the elimination of cervical cancer.

30 **Materials and Methods:** This review will consider studies that pertain to implementation
31 strategies used to increase HPV vaccination uptake for adolescent girls in sub-Saharan Africa.
32 Studies targeted at different stakeholders to increase adolescent vaccine uptake will be included.
33 Studies using interventions not fitting the definition of implementation strategies as defined by
34 the refined compilation of implementation strategies from the Expert Recommendations for
35 Implementing Change project will be excluded. MEDLINE (via PubMed), Embase, CINAHL
36 (via EBSCO), Scopus and Google scholar will be searched. Two independent reviewers will
37 screen titles and abstracts for studies that meet the review's inclusion criteria, and the full text of
38 eligible studies will be reviewed. Data will be extracted from eligible studies using data charting
39 table developed by this team for inclusion by two independent reviewers and presented in table
40 and graphical form with a narrative summary.

41 **Keywords**

42 cervical cancer elimination; immunisation; adolescent girls; acceptability; vaccine hesitancy,
43 HPV vaccine.

44 **Introduction**

45 The human papillomavirus (HPV) is sexually transmitted and affects approximately 75% of
46 sexually active people early in their sexual life [1,2]. There are more than 200 species of HPVs
47 categorized into low risk (causing warts) and high-risk types (causing cancers) [3]. The point
48 prevalence of HPV infection is estimated at 11–12% globally and 22–24% for sub-Sahara Africa
49 (SSA) [4-7]. HPV infection is mainly asymptomatic and transient, with approximately 90%
50 cleared in immunocompetent people but persists in about 10-20 % [2]. Immunocompromised
51 people, such as those living with HIV, are more likely to have persistent HPV infections, which
52 usually progress more rapidly to pre-cancers and cancers than in the general population [8].
53 Cancers caused by HPV include the anal-genital and the head and neck regions, with the highest
54 burden in sub-Saharan Africa [5].

55 In 2006, the World Health Organisation (WHO) approved the use of HPV vaccines for
56 prepubertal girls aged 9 to 14 years, naive to sexual intercourse to prevent HPV related
57 conditions [2]. There are currently four licensed HPV vaccines classified as bivalent,
58 quadrivalent and nonavalent based on the number of targeted HPV strains [9]. From 2006 to
59 2014, three doses were recommended to complete the vaccination schedule; however, evolving
60 evidence has shown that two doses are effective, leading WHO to recommend two doses for girls
61 below the age of 15 [10], with ongoing studies showing promise for an efficacious and cost-
62 effective single-dose HPV vaccine [11]. The three-dose schedule is now reserved for girls older
63 than 15 years or those who are immunocompromised, including those who are HIV positive [9].
64 The reduced number of doses is envisioned to boost vaccine coverage and reduce barriers to
65 vaccination such as multiple visits to the health facility, human resource demand and cost of the
66 vaccine [12-15].

67 Barriers to HPV vaccination have been identified within sub-Saharan Africa (SSA), and the
68 implementation of national programs remains a challenge at both initiation and sustainability
69 levels [16]. Some of the identified barriers to HPV vaccine uptake include individual, structural,
70 economic and community/social, cultural issues [14,17]. There is a dire need at the global level
71 to increase HPV vaccine uptake with the accelerated global strategy for cervical cancer
72 elimination whose target is to have 90% of girls aged 15 should be fully vaccinated by 2030 [18].

73 The impact of HPV vaccination in reducing HPV related diseases is evident in high-income
74 countries which introduced national immunization programs earlier. For example, a meta-
75 analysis of fourteen high-income countries implementing the HPV vaccination program reported
76 a reduction in the prevalence of HPV 16 and 18 by 83% among girls aged 13–19 years and by
77 66% among women aged 20–24 years with significant cross-protection from HPV 31, 33 and 45
78 [19]. Furthermore, emerging data from the UK has shown that ten years after implementing the
79 HPV vaccination to adolescent girls aged 12-13 years, cervical cancer has almost been
80 eliminated [20]. However, many SSA countries are still trailing behind in implementing the
81 national HPV vaccination in a backdrop of low uptake in countries that have already
82 implemented the program despite having the highest HPV related morbidity and mortality
83 [12,21].

84 The point of the HPV vaccination programme is to get vaccines to those who need to receive
85 them and mitigate future preventable diseases such as cervical cancer. For interventions such as
86 the HPV vaccination to achieve success (intervention effectiveness) in a real-world setting, they
87 have to be implemented well and in ways that can reach the target groups. This often requires
88 implementation strategies that are enacted to overcome any implementation bottlenecks [22].
89 According to Powel and others, an implementation strategy is defined as “a systematic
90 intervention process to adopt and integrate evidence-based health innovations into usual care”
91 [22]. Therefore, to successfully implement the HPV vaccine and harness the benefits,
92 implementation strategies should be tailored to a real-life situation. For example, a study
93 conducted by Chigbu et al [23] in Nigeria used educational intervention [implementation
94 strategy] to increase HPV vaccine uptake for adolescent girls from 0.9% to 33.2% in a pre and
95 post design method. Another study done in South Africa used multiple implementation strategies
96 such as building a coalition, conducting educational meetings, conducting educational outreach
97 visits, developing educational materials, distributing educational materials, mandate change,
98 obtaining and using consumers feedback and saw adolescent HPV vaccine uptake of up to 87%
99 [24].

100 There is a consensus among researchers that implementation strategies that work in one region
101 may not necessarily work in another; therefore, implementation strategies should be tailored
102 according to the context in which they will be implemented in a real-life context [22]. Therefore,
103 it is urgent to have evidence from SSA, one of the regions with the highest burden of HPV
104 infection and align with the global strategy for elimination of cervical cancer [18]. Therefore,
105 this scoping review aims to identify implementation strategies used in SSA to increase HPV
106 vaccine uptake for adolescent girls. The findings of this review will provide a basis for policy
107 and future research including systematic reviews to understand which implementation strategies
108 are effective in SSA in tandem with the recommendations by the WHO Africa region leadership
109 [16].

110 A preliminary review of the literature was conducted in December 2021 in PROSPERO,
111 PubMed, Scopus, Google scholar, JBI evidence synthesis database; no similar scoping review
112 has been done or is underway in the context of SSA. Even though a narrative review was
113 conducted on HPV vaccine in SSA in 2020 focusing on a 10 year period of HPV vaccination

114 research in Tanzania, a narrative review uses an implicit process to compile evidence hence has
115 weaknesses such as a lack of systematic selection of studies and is likely to reinforce authors'
116 own preconceived ideas and experiences leading to bias [26]. On the other hand, our scoping
117 review will be comprehensive with a clear inclusion and exclusion criteria, and will transparently
118 synthesise the available evidence to minimize similar limitations.

119 **Review question**

120 What implementation strategies have increased the uptake of HPV vaccination for adolescent
121 girls in sub-Saharan Africa?

122 **Objective**

123 To identify implementation strategies to increase HPV vaccination uptake for adolescent girls in
124 sub-Saharan Africa and provide a basis for future systematic reviews to evaluate effective
125 strategies.

126 **Materials and Methods**

127 The proposed scoping review will be conducted following the Joanna Briggs Institute (JBI)
128 updated methodology for scoping reviews [27]. This scoping review is registered in Open
129 Science Framework projects-<https://osf.io/gfd7s/>.

130 **Inclusion criteria**

131 **Participants:** Participants will include all stakeholders involved in the cascade of HPV
132 vaccination such as studies on adolescent girls aged 9-14 years as the primary recipients and
133 those aged 15-19 years old who may be eligible for subsequent doses. This scoping review will
134 also include studies that focus on parents/guardians of adolescent girls as they are involved in the
135 consent process for the vaccination of their daughters. Further, studies involving healthcare
136 workers will also be included considering that healthcare providers play a crucial role in
137 recommending and administering the vaccine to eligible. Studies involving teachers and other
138 community leaders will also be considered.

139 **Concept:** We will include studies that used at least one of the implementation strategies as
140 defined by the refined compilation of implementation strategies from the Expert
141 Recommendations for Implementing Change (ERIC) project [28], to increase uptake of HPV
142 vaccination. The ERIC expert panel achieved consensus on 73 discrete implementation
143 strategies, including their definitions [28]. Some examples of these implementations strategies
144 include; i) conduct educational meetings defined as “hold meetings targeted toward different
145 stakeholder groups to teach them about the clinical innovation,” ii) build a coalition defined as
146 “recruit and cultivate relationships with partners in the implementation effort,” iii) access new
147 funding defined as “ access new or existing money to facilitate the implementation” [25].

148 Considering that not all interventions may be reported as implementation strategies, we will read
149 through all the studies mentioning interventions to check which ones meet the definitions by the
150 ERIC project and classify them during data charting. Studies including interventions other than
151 those based on the refined compilation of implementation strategies from the ERIC project will
152 be excluded.

153 **Context:** This review will consider studies done in sub-Saharan Africa aimed at improving the
154 uptake of the HPV vaccine among adolescent girls.

155 **Types of sources**

156 This scoping review will consider experimental and quasi-experimental study designs, including
157 randomized controlled trials, non-randomized controlled trials, before and after studies and
158 interrupted time-series studies. In addition, analytical observational studies including prospective
159 and retrospective cohort studies, case-control studies and analytical cross-sectional studies will
160 be considered for inclusion. We will also consider descriptive observational study designs and
161 qualitative studies. In addition, systematic reviews that meet the inclusion criteria will also be
162 considered, depending on the research question. Text and opinion papers will also be considered.

163 **Search strategy**

164 An initial limited search of MEDLINE (PubMed), EMBASE and Scopus was undertaken to
165 identify articles on the topic. The text words contained in the titles and abstracts of relevant
166 articles and the index terms used to describe the articles were used to develop a full search

167 strategy for MEDLINE (PubMed) (S1 Appendix 1). The search strategy will aim to locate both
168 published and unpublished studies. The search strategy, including all identified keywords and
169 index terms, will be adapted for each included database and information source. The reference
170 list of included sources of evidence will be screened for additional studies. The section for
171 similar articles will also be searched on MEDLINE (PubMed).

172 Studies published in any other language apart from English will not be included as the teams'
173 competence does not go beyond the English language. Studies published starting in 2006 will be
174 included as this was when WHO approved the use of the HPV vaccine among prepubertal girls,
175 the search will include studies published until December 31st 2021.

176 The databases to be searched include MEDLINE (via PubMed), EMBASE, CINAHL
177 (Cumulative Index to Nursing and Allied Health Literature) (EBSCO) and Scopus. Grey
178 literature citations (unpublished, nonpeer review data sources including conference proceedings,
179 abstracts and dissertations) indexed by any of the databases searched will be reviewed with other
180 peer-reviewed publications using the same inclusion and exclusion criteria. Further, the first 50
181 hits from the Google scholar search engine will be reviewed for possible inclusion. A medical
182 librarian/ information specialist will guide the search.

183 Following the search, all identified studies will be collated and uploaded into Endnote X9
184 (Clarivate Analytics, USA) and duplicates removed after which they will be imported into the
185 Joanna Briggs Institute System for the Unified Management, Assessment and Review of
186 Information (JBI SUMARI) [29]. Two independent reviewers will screen titles and abstracts for
187 assessment against the inclusion criteria for the review and potentially relevant studies will be
188 retrieved in full and their citation details in JBI SUMARI. The full text of selected citations will
189 be assessed in detail against the inclusion criteria by two independent reviewers. The scoping
190 review will record and report reasons for the exclusion of full-text studies that do not meet the
191 inclusion criteria. Any disagreements that arise between the reviewers at each stage of the study
192 selection process will be resolved through discussion or with a third reviewer if consensus is not
193 reached. The search is planned to start on 31st May 2022. The search results will be reported in
194 full in the final scoping review and presented in a Preferred Reporting Items for Systematic
195 Reviews and Meta-analyses extension for scoping reviews (PRISMA-ScR) flow diagram [30].

196

197

198 **Data extraction**

199 Data will be extracted from papers included in the scoping review by two independent reviewers
200 using a data extraction chart developed by the reviewers (SI 2 Appendix II). The data extracted
201 will include; first author, year of study, year of publication, country, the title of the article, article
202 type, study design (where applicable), sample size, implementation strategy(ies), targeted
203 stakeholders, type of program (national program/demonstration/subpopulation, funding source,
204 HPV vaccine coverage/uptake, limitations and strengths. The draft extraction chart will be
205 piloted on 5 included pieces of evidence and revisions made if necessary. The draft data
206 extraction tool will further be modified and revised as necessary during the process of data
207 charting from each included evidence source. Modifications will be detailed in the scoping
208 review. Authors of papers will be contacted to request missing or additional data, where
209 required, if no response will be received within two weeks, available data will be used in the best
210 possible way.

211 **Data presentation**

212 The scoping review reporting will align with the PRISMA-ScR [30]. The extracted data will be
213 presented in table or graphical form to align with the study objectives. These will be
214 accompanied by a narrative summary of how the findings relate to the research question and
215 objectives.

216 **Patient and public involvement statement**

217 Patients and the public were not involved in the design of this study.

218 **Discussion**

219 A narrative summary of findings will be provided and discussed.

220 **Limitations**

221 This scoping review will only focus on studies done in English hence may miss other important
222 research done in other languages. Further, only implementation strategies focusing on uptake of
223 the vaccine for girls will be considered, yet there could be other unique and successful
224 interventions used to increase HPV vaccine uptake among boys. However, these maybe few as
225 most countries in SSA are currently implementing girls only programmes.

226 **Ethics and Dissemination plans**

227 Ethical approval is not applicable since no primary data will be collected. Dissemination of
228 results will be through publications, conferences and stakeholder meetings. In case of any
229 amendments to the protocol following its publication, amendments and rationale will be
230 described in future publications arising from this protocol.

231 **Author contributions:** MKL: Conceptualised and drafted the initial manuscript, MMW &
232 conducted the pilot search in Pubmed, all authors revised subsequent manuscript drafts and
233 approved the final draft for publication.

234 **Acknowledgements**

235 We would like to acknowledge the support from the University of Zambia-University of North
236 Carolina at Chapel Hill and Witwatersrand University consortium PhD fellowship program.

237 **References**

238 1. Loke AY, Kwan ML, Wong YT, Wong AKY The Uptake of Human Papillomavirus
239 Vaccination and Its Associated Factors Among Adolescents: A Systematic Review. J prim care
240 community health. 2017;8(4):349-62.

241 2. World Health Organization. (2009). Weekly Epidemiological Record, 2009, vol. 84, 22 [full
242 issue]. *Weekly Epidemiological Record = Relevé épidémiologique hebdomadaire*, 84 (22), 197 –
243 212. Accessed from: <https://apps.who.int/iris/handle/10665/241342>

244 3. Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, et al.
245 Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.

246 4. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global
247 burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12-23.

- 248 5. De Vuyst H, Alemany L, Lacey C, Chibwesa CJ, Sahasrabuddhe V, Banura C, et al. The
249 burden of human papillomavirus infections and related diseases in sub-Saharan Africa. *Vaccine*.
250 2013;31 Suppl 5(0 5):F32-46.
- 251 6. Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical Human
252 Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal
253 Cytological Findings. *The Journal of Infectious Diseases*. 2010;202(12):1789-99.
- 254 7. De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide
255 prevalence and genotype distribution of cervical human papillomavirus DNA in women with
256 normal cytology: a meta-analysis. *The Lancet Infectious Diseases*. 2007;7(7):453-9.
- 257 8. Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P. Association of antiretroviral
258 therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive
259 cervical cancer in women living with HIV: a systematic review and meta-analysis. *The Lancet*
260 *HIV*. 2018;5(1):e45-e58.
- 261 9. World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper,
262 October 2014. *Wkly Epidemiol Rec*. 2014;89(43):465–92 [cited on 2020 July 10] Available
263 from: <http://www.who.int/wer/2014/wer8943.pdf>
- 264 10. World Health Organization. Evidence-based recommendations on Human Papilloma Virus
265 (HPV) vaccines schedules: Background paper for SAGE discussions. March 11, 2014.[cited on
266 2020July10]Available from:
267 https://www.who.int/immunization/sage/meetings/2014/april/1_HP_V_evidence_based_recommen
268 [ndationsWHO_with_Appendices2_3.pdf](https://www.who.int/immunization/sage/meetings/2014/april/1_HP_V_evidence_based_recommen)
- 269 11. Burger EA, Campos NG, Sy S, Regan C, Kim JJ. Health and economic benefits of single-
270 dose HPV vaccination in a Gavi-eligible country. *Vaccine*. 2018;36(32, Part A):4823-9.
- 271 12. Kisaakye E, Namakula J, Kihembo C, Kisakye A, Nsubuga P, Babirye JN. Level and factors
272 associated with uptake of human papillomavirus infection vaccine among female adolescents in
273 Lira District, Uganda. *The Pan African medical journal*. 2018;31:184.
- 274 13. Pugliese-Garcia M, Heyerdahl LW, Mwamba C, Nkwemu S, Chilengi R, Demolis R, et al.
275 Factors influencing vaccine acceptance and hesitancy in three informal settlements in Lusaka,
276 Zambia. *Vaccine*. 2018;36(37):5617-24.
- 277 14. Wigle J, Coast E, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in
278 low and middle-income countries (LMICs): health system experiences and prospects. *Vaccine*.
279 2013;31(37):3811-7.
- 280 15. Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA. Infrastructure Requirements
281 for Human Papillomavirus Vaccination and Cervical Cancer Screening in Sub-Saharan Africa.
282 *Vaccine*. 2013;31:F47-F52.
- 283 16. Framework for the implementation of the global strategy to accelerate the elimination of
284 cervical cancer as a public health problem in the who african region. 2021 Report AFR/RC71/9

- 285 [cited on 2022 April 7] Available from: [https://www.afro.who.int/about-](https://www.afro.who.int/about-us/governance/sessions/seventy-first-session-who-regional-committee-africa)
286 [us/governance/sessions/seventy-first-session-who-regional-committee-africa](https://www.afro.who.int/about-us/governance/sessions/seventy-first-session-who-regional-committee-africa)
- 287 17. World Health Organization global strategy to accelerate the elimination of cervical cancer as
288 a public health problem. 2020. Report No.: ISBN 978-92-4-001410-7.[cited on 2021 March 17]
289 Available from: <https://www.who.int/publications/i/item/9789240014107>
- 290 18. Drolet M, Bénard É, Pérez N, Brisson M. Population-level impact and herd effects following
291 the introduction of human papillomavirus vaccination programmes: updated systematic review
292 and meta-analysis. *Lancet* (London, England). 2019;394(10197):497-509.
- 293 19. Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of
294 the national HPV vaccination programme in England, UK, on cervical cancer and grade 3
295 cervical intraepithelial neoplasia incidence: a register-based observational study. *The Lancet*.
296 2021;398(10316):2084-92.
- 297 20. Dorji T, Nopsopon T, Tamang ST, Pongpirul K. Human papillomavirus vaccination uptake
298 in low-and middle-income countries: a meta-analysis. *EClinical medicine*. 2021;34:100836.
- 299 21. Rujumba J, Akugizibwe M, Basta NE, Banura C. Why don't adolescent girls in a rural
300 Uganda district initiate or complete routine 2-dose HPV vaccine series: Perspectives of
301 adolescent girls, their caregivers, healthcare workers, community health workers and teachers.
302 *PloS one*. 2021;16(6):e0253735.
- 303 22. Powell BJ, McMillen JC, Proctor EK, Carpenter CR, Griffey RT, Bunger AC, et al. A
304 compilation of strategies for implementing clinical innovations in health and mental health. *Med*
305 *Care Res Rev*. 2012;69(2):123-57.
- 306 23. Chigbu CO, Onyebuchi AK, Onyeka TC, Odugu BU, Dim CC. The impact of community
307 health educators on uptake of cervical and breast cancer prevention services in Nigeria. *Int J*
308 *Gynaecol Obstet*. 2017 Jun;137(3):319-324. doi: 10.1002/ijgo.12150. Epub 2017 Mar 31. PMID:
309 28295268.
- 310 24. Delany-Moretlwe S, Kelley KF, James S, Scorgie F, Subedar H, Dlamini NR, Pillay Y,
311 Naidoo N, Chikandiwa A, Rees H. Human Papillomavirus Vaccine Introduction in South Africa:
312 Implementation Lessons From an Evaluation of the National School-Based Vaccination
313 Campaign. *Glob Health Sci Pract*. 2018 Oct 4;6(3):425-438. doi: 10.9745/GHSP-D-18-00090.
314 PMID: 30143561; PMCID: PMC6172125.
- 315 25. Whitworth H, Changalucha J, Baisley K, Watson-Jones D. Adolescent Health Series: HPV
316 infection and vaccination in sub-Saharan Africa: 10 years of research in Tanzanian female
317 adolescents - narrative review. *Trop Med Int Health*. 2021 Nov;26(11):1345-1355. doi:
318 10.1111/tmi.13660. Epub 2021 Sep 1. PMID: 34310816.
- 319 26. Garg AX, Hackam D, Tonelli M. Systematic review and meta-analysis: when one study is
320 just not enough. *Clin J Am Soc Nephrol*. 2008 Jan;3(1):253-60. doi: 10.2215/CJN.01430307.
321 PMID: 18178786.

322 27. Peters MDJ, Marnie C, Tricco AC, Pollock D, Munn Z, Alexander L, et al. Updated
323 methodological guidance for the conduct of scoping reviews. JBI Evidence Synthesis.
324 2020;18(10):2119-26.

325 28. Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, et al. A
326 refined compilation of implementation strategies: results from the Expert Recommendations for
327 Implementing Change (ERIC) project. Implementation Science. 2015;10(1):21.

328 29. Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J, et al. The development of
329 software to support multiple systematic review types: the Joanna Briggs Institute System for the
330 Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid Based
331 Healthc. 2019 Mar;17(1):36-43. doi: 10.1097/XEB.000000000000152. PMID: 30239357.

332 30. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
333 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med.
334 2018;169(7):467-73.

335

336